The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Liso-cel for aggressive B-cell NHL
Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, discusses results from the Phase II TRANSCEND-PILOT-017006 study (NCT03483103) evaluating lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in relapsed/refractory large B-cell non-Hodgkin lymphoma (NHL) patients. Specifically discussed is the potential impact of this CAR T-cell therapy on elderly, unfit patients with comorbidities. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
